tozadenant

Tozadenant is a small molecule drug that acts as an adenosine A2A receptor antagonist. It was developed primarily as an adjunctive treatment to levodopa for Parkinson's disease, aiming to reduce "off" time in patients experiencing motor fluctuations. The drug works by blocking the adenosine A2A receptor, which modulates neurotransmitter release (including dopamine) in the brain, thereby potentially improving motor function in Parkinson's disease. Tozadenant reached phase III clinical trials but development was terminated due to safety concerns, including cases of agranulocytosis and associated serious adverse events such as sepsis. The original developer was Roche; later development was led by Biotie Therapies and subsequently Acorda Therapeutics[3][6][7].

Other names

4-hydroxy-N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxamide